Novartis AG has a consensus price target of $32.86, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, BMO Capital, and Morgan Stanley on April 24, 2024, February 23, 2024, and January 23, 2024. With an average price target of $114.67 between BMO Capital, BMO Capital, and Morgan Stanley, there's an implied 9.34% upside for Novartis AG from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/24/2024 | Buy Now | 10.61% | BMO Capital | Etzer Darout | $114 → $116 | Maintains | Market Perform | Get Alert |
02/23/2024 | Buy Now | 8.71% | BMO Capital | Etzer Darout | → $114 | Initiates | → Market Perform | Get Alert |
01/23/2024 | Buy Now | 8.71% | Morgan Stanley | Mark Purcell | → $114 | Initiates | → Equal-Weight | Get Alert |
09/25/2023 | Buy Now | — | Morgan Stanley | Vincent Meunier | — | Upgrade | Underweight → Equal-Weight | Get Alert |
05/09/2022 | Buy Now | — | Wolfe Research | Tim Anderson | — | Downgrade | Outperform → Peer Perform | Get Alert |
12/06/2021 | Buy Now | — | Exane BNP Paribas | Richard Parkes | — | Downgrade | Outperform → Neutral | Get Alert |
12/03/2021 | Buy Now | — | Bryan Garnier | Jeanjacques Le Fur | — | Downgrade | Buy → Neutral | Get Alert |
09/20/2021 | Buy Now | — | Deutsche Bank | Emmanuel Papadakis | — | Downgrade | Hold → Sell | Get Alert |
The latest price target for Novartis (NYSE: NVS) was reported by BMO Capital on April 24, 2024. The analyst firm set a price target for $116.00 expecting NVS to rise to within 12 months (a possible 10.61% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Novartis (NYSE: NVS) was provided by BMO Capital, and Novartis maintained their market perform rating.
The last upgrade for Novartis AG happened on September 25, 2023 when Morgan Stanley raised their price target to N/A. Morgan Stanley previously had an underweight for Novartis AG.
The last downgrade for Novartis AG happened on May 9, 2022 when Wolfe Research changed their price target from N/A to N/A for Novartis AG.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
While ratings are subjective and will change, the latest Novartis (NVS) rating was a maintained with a price target of $114.00 to $116.00. The current price Novartis (NVS) is trading at is $104.87, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.